As the most famous selective COX-2 inhibitor, celecoxib has highly therapeutic potential for treatment of GBM (Giglio and Levin, 2004), which may be mediated by inhibiting the cell cycle (Kardosh et al., 2004), inducing DNA damage (Kang et al., 2009), and promoting apoptosis (Sareddy et al., 2012) and necrosis (Kang et al., 2007) of GBM cells. The gene discussed is PTGS2; the disease is glioblastoma.